Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BI
BioVie, Inc. Common Stock
BIVI
Mkt Cap
$10.5M
Volume
264.16K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
BI
BIVI
BI
BioVie, Inc. Common Stock
BIVI
News
·
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9
Mkt Cap
$10.4M
Volume
264.16K
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9
BioVie Inc. will host an investor webinar on December 9, 2025, featuring CEO Cuong Do discussing their drug candidates bezisterim and BIV201 for neurological diseases and liver cirrhosis, highlighting clinical progress and potential market opportunities.
GlobeNewswire Inc. · Nov 19, 2025
BioVie to Host Live Investor Webinar and Q&A on Oct. 8
BioVie Inc. will host an investor webinar discussing its drug therapies for neurological diseases, focusing on bezisterim for Alzheimer's, Parkinson's, and long COVID, and BIV201 for liver cirrhosis complications.
GlobeNewswire Inc. · Sep 26, 2025
BioVie Inc. Announces Pricing of $12 Million Public Offering
BioVie Inc. has priced a public offering of 6 million units at $2.00 per unit, expecting to raise approximately $12 million. The offering includes common stock and warrants, with proceeds intended for working capital and general corporate purposes.
Benzinga · Aug 8, 2025
BioVie Inc. Announces Pricing of $12 Million Public Offering
BioVie Inc. is pricing a public offering of 6 million units, each consisting of one common stock share and one warrant, expected to raise approximately $12 million for working capital and general corporate purposes.
GlobeNewswire Inc. · Aug 8, 2025
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology
BioVie presented research showing its drug Bezisterim potentially reduces biological age in Alzheimer's patients by modulating DNA methylation across multiple biological clocks, with significant improvements in inflammatory and metabolic biomarkers.
GlobeNewswire Inc. · Jul 24, 2025
Alzheimer’s Therapeutics Market on Upward Trajectory Across the 7MM During the Forecast Period (2025–2034) Fueled by Drug Development Advances | DelveInsight
The Alzheimer's disease market is expected to grow significantly between 2025-2034, driven by emerging therapies targeting disease mechanisms and improved diagnostic capabilities, with the US market representing approximately 50% of the total market size.
GlobeNewswire Inc. · Jul 8, 2025
BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against BioVie Inc. on behalf of long-term stockholders following a class action complaint alleging the company made materially false and/or misleading statements about its business, operations, and prospects.
GlobeNewswire Inc. · May 1, 2025
BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled
BioVie has initiated the SUNRISE-PD clinical trial to evaluate the safety and efficacy of its drug candidate bezisterim in patients with early-stage Parkinson's disease. The trial will incorporate a decentralized approach to allow for remote participation, and is supported by leading Parkinson's foundations.
GlobeNewswire Inc. · Apr 16, 2025
BioVie Inc. Announces Pricing of Public Offering
BioVie Inc. (NASDAQ: BIVI) announced the pricing of a $3 million public offering of 1,960,800 shares of its common stock and associated warrants. The company plans to use the net proceeds for working capital and general corporate purposes.
GlobeNewswire Inc. · Sep 24, 2024
BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID
BioVie received FDA authorization to evaluate its drug bezisterim in a Phase 2 trial for treating neurological symptoms associated with long COVID. The trial is supported by a $12.6 million grant from the U.S. Department of Defense.
GlobeNewswire Inc. · Sep 3, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
BI
BIVI
BioVie, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
BIVI
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any BIVI yet.
Related Tickers
Earnings